Drug
IMSA101
IMSA101 is a pharmaceutical drug with 5 clinical trials. Currently 2 active trials ongoing. Historical success rate of 33.3%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
2(40%)
Results Posted
200%(2 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_2
3
60%
Phase Distribution
2
Early Stage
3
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
2
trials recruiting
Total Trials
5
all time
Status Distribution
Active(2)
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
2
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (40.0%)
Phase 23 (60.0%)
Trials by Status
active_not_recruiting120%
completed120%
recruiting120%
terminated240%
Recent Activity
2 active trials
Showing 5 of 5
recruitingphase_2
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
NCT06601296
terminatedphase_2
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
NCT05846646
completedphase_1
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
NCT04020185
terminatedphase_2
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
NCT05846659
active_not_recruitingphase_1
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
NCT06026254
Clinical Trials (5)
Showing 5 of 5 trials
NCT06601296Phase 2
Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer
NCT05846646Phase 2
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
NCT04020185Phase 1
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
NCT05846659Phase 2
Study of PULSAR-ICI +/- IMSA101 in Patients with Oligoprogressive Solid Tumor Malignancies
NCT06026254Phase 1
A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5